
A recent study indicates that Janus Kinase (JAK) inhibitors effectively treat refractory granulomatous diseases. A case involving a 50-year-old woman who developed a granulomatous reaction after a filler injection in her buttocks is reported. The patient received treatment with tofacitinib, leading to the resolution of stiffness and swelling after one year of therapy, with no reported side effects. The case suggests that tofacitinib may be viable for managing granulomatous reactions to cosmetic fillers, providing a new therapeutic avenue for similar clinical challenges.
Like
Save
Share